11 completed, 2 recruiting, 2 withdrawn, 1 not yet recruiting. 18 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Completed 11, Recruiting 2, Withdrawn 2, Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Withdrawn 1 |
Follow Shock, Hemorrhagic: new trials by email Literature Review of Shock, Hemorrhagic trials Research Report on Shock, Hemorrhagic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Optimization Strategies for Blood Transfusion Protocols in the Emergency Treatment of Hemorrhagic Shock low-titer O-group whole blood, 1:1:1 component transfusion, ABO- and Rh-compatible whole blood - Hemorrhage, Hemorrhagic Shock | Phase 3 | Not yet recruiting | Xijing Hospital | 180 | 2025-09-01 | 2025-08-19 |
| Empiric Calcium in Massive Transfusion Calcium Gluconate - Hemorrhage, Trauma | Phase 3 | Withdrawn | University of California, Irvine | 2025-01-01 | 2026-03-30 | |
| Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children Low Titer Group O Whole Blood (LTOWB), Placebo, Tranexamic Acid (TXA) - Hemorrhagic Shock, Trauma Injury | Phase 3 | Recruiting | Philip Spinella | 1000 | 2024-11-01 | 2026-09-17 |
| Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock Patients Protonix (Pantoprazole) 40 mg q 12 hrs for 2 days, Protonix (pantoprazole) 40 mg q 24 hrs for 2 days - Acute Kidney Injury | Phase 2 / Phase 3 | Recruiting | The University of Texas Health Science Center, Houston | 100 | 2024-09-07 | 2026-02-19 |
| Trauma Resuscitation With Low-Titer Group O Whole Blood or Products LTOWB, Components - Wounds and Injuries, Shock, Hemorrhagic | Phase 3 | Completed | University of Alabama at Birmingham | 1100 | 2023-07-27 | 2026-09-22 |
| Fibrinogen Early In Severe Trauma StudY II Fibrinogen Concentrate, Cryoprecipitate - Trauma, Haemorrhagic Shock | Phase 3 | Completed | Australian and New Zealand Intensive Care Research Centre | 900 | 2022-11-21 | 2026-09-09 |
| Type O Whole Blood and Assessment of Age During Prehospital Resuscitation Trial low titer whole blood, Standard Care - Hemorrhagic Shock, Traumatic Injury | Phase 3 | Completed | Jason Sperry | 1020 | 2022-04-19 | 2026-02-12 |
| Low-Titer O Positive Whole Blood Versus Component Therapy for Emergent Transfusion in Trauma Patients Routine labs - Hemorrhagic Shock, Acute Blood Loss Anemia | Phase 3 | Completed | Loma Linda University | 199 | 2022-03-05 | 2025-08-08 |
| Pragmatic Prehospital Group O Whole Blood Early Resuscitation Trial Whole blood - Hemorrhagic Shock | Phase 3 | Terminated | Jason Sperry | 86 | 2018-11-20 | 2021-10-06 |
| Transfusion of Red Blood Cells, Tranexamic Acid and Fibrinogen Concentrate for Severe Trauma Hemorrhage with red blood cells (RBC), Tranexamic acid (TXA) and Fibrinogen Concentrate (FC),administration of Crystalloids and TXA., conventional treatment - Hemorrhagic Shock | Phase 3 | Completed | Cristina Martinez | 30 | 2018-09-26 | 2023-10-06 |
| Early Administration of Prothrombin Concentrate Complex in Patients With Acute Hemorrhage Following Severe Trauma Pro-Thrombin Concentrate Complex, NaCl 0.9% - Shock, Hemorrhagic | Phase 3 | Completed | University Hospital, Grenoble | 350 | 2017-12-29 | 2022-11-08 |
| Pre-hospital Administration of Lyophilized Plasma for Post-traumatic Coagulopathy Treatment (PREHO-PLYO) French Lyophilized Plasma, Normale Saline Solution - Shock Hemorrhagic | Phase 3 | Completed | French Defence Health Service | 140 | 2016-04-01 | 2020-01-07 |
| California Prehospital and In Hospital Antifibrinolytic Therapy Via TXA Tranexamic Acid - Hemorrhagic Shock, Trauma Injury | Phase 3 | Completed | Arrowhead Regional Medical Center | 200 | 2015-03-01 | 2024-07-30 |
| Pre-Hospital Use of Plasma for Traumatic Hemorrhage Plasma, Normal saline - Shock, Hemorrhagic | Phase 2 / Phase 3 | Withdrawn | Virginia Commonwealth University | 2014-11-01 | 2016-02-23 | |
| Pragmatic, Randomized Optimal Platelet and Plasma Ratios 1:1:1 Blood Transfusion Ratio, 1:1:2 Blood Transfusion Ratio - Trauma | Phase 3 | Completed | The University of Texas Health Science Center, Houston | 680 | 2012-08-01 | 2019-02-08 |
| Vasopressin in Traumatic Hemorrhagic Shock Study Vasopressin, Saline placebo - Shock, Hypovolemia | Phase 2 / Phase 3 | Completed | Volker Wenzel | 64 | 2010-07-01 | 2014-11-05 |
| Efficacy, Safety of Solution Containing Hyperosmolar Sodium Lactate Infusion for Resuscitation of Patients With Hemorrhagic Shock Hyperosmolar sodium lactate, Ringer's lactate - Hemorrhagic Shock | Phase 3 | Completed | Innogene Kalbiotech Pte. Ltd | 71 | 2009-07-01 | 2011-09-13 |
| Safety and Efficacy of PolyHeme(R) in Hemorrhagic Shock Following Traumatic Injuries Beginning in the Pre-Hospital Setting Poly SFH-P Injection - Hemorrhagic Shock | Phase 3 | Unknown | Northfield Laboratories | 2006-08-02 |
Hemorrhage (7) · Wounds and Injuries (7) · Shock (4) · Accidental Injuries (2) · Hemostatic Disorders (2) · Acute Kidney Injury (1) · Brain Injuries, Traumatic (1) · Diabetes Insipidus (1) · Gastrointestinal Hemorrhage (1) · Hypocalcemia (1) · Hypovolemia (1) · Inflammation (1) · Multiple Trauma (1) · Pathologic Processes (1)
Pathological Conditions, Signs and Symptoms (18) · Pathologic Processes (17) · Shock (14) · Hemorrhage (11) · Wounds and Injuries (3) · Cardiovascular Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Hemorrhagic Disorders (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Urogenital Diseases (2) · Urologic Diseases (2)
Tranexamic Acid (3) · Sodium Chloride (2) · Calcium (1) · Calcium Gluconate (1) · Elements (1) · Erythrocyte Count (1) · Fibrinogen (1) · Pantoprazole (1) · Ringer's Lactate (1) · Saline Solution (1) · Standard of Care (1) · Vasopressins (1) · cryoprecipitate coagulum (1) · polyhemoglobin-pyridoxal-5-phosphate (1)
Jason Sperry (2) · The University of Texas Health Science Center, Houston (2) · Arrowhead Regional Medical Center (1) · Australian and New Zealand Intensive Care Research Centre (1) · Cristina Martinez (1) · French Defence Health Service (1) · Innogene Kalbiotech Pte. Ltd (1) · Loma Linda University (1) · Northfield Laboratories (1) · Philip Spinella (1) · University Hospital, Grenoble (1) · University of Alabama at Birmingham (1) · University of California, Irvine (1) · Virginia Commonwealth University (1) · Volker Wenzel (1)
United States (9) · France (2) · Australia (1) · Austria (1) · Canada (1) · China (1) · Germany (1) · Indonesia (1) · New Zealand (1) · Spain (1)
Bruce D Spiess, MD, FAHA (1) · Jan Jansen, MBBS, PhD (1) · Jason L Sperry, MD (1) · Jason Sperry, MD (1) · Jeffry Nahmias, MD (1) · John Holcomb, MD (1) · Jordi Vila, MD (1) · Kiki Lukman, SpBD(K) (1) · Michael Neeki (1) · Philip C Spinella, MD (1)
PMID 25647203, PMID 38531812, PMID 40271704, PMID 17109736, PMID 18090009, PMID 19228496, PMID 21112053, PMID 21332727, PMID 24335442, PMID 24996573, PMID 25816119, PMID 25947955, PMID 26002260, PMID 26220293, PMID 26680132, PMID 28183347, PMID 28611888, PMID 28731937, PMID 28930959, PMID 29766088, PMID 30030268, PMID 30447946, PMID 31050809, PMID 31969168, PMID 33797501, PMID 34530886, PMID 35081595, PMID 35881397, PMID 36942533, PMID 37058726, PMID 38342992, PMID 38933603, PMID 39898869, PMID 40237834, PMID 40420619, PMID 40753420, PMID 42150044
1UG3HL157401-01A1 (1), R34HL135224 (1), U01HL077863 (1), U24HL157310 (1)